Comparing different surgical methods for prostate cancer treatment
Official title: Comparison of Radical Prostatectomy for the Treatment of Prostate Cancer, Performed by Robot-assisted or Standard Laparoscopy or by Laparotomy : a Multicentric Prospective Study.
Run by Elsan · NCT04638088 · Data updated 2026-11-12
This study is testing which surgical method—robot-assisted laparoscopy, conventional laparoscopy, or laparotomy—works best for treating prostate cancer and how they affect urinary and erectile function after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 2000 (estimated) |
| Sponsor | Elsan Academic / other |
| Locations | 30 sites (Agen and 29 other locations) |
| Status | Recruiting |
| Started | March 8, 2021 |
| Main results expected | July 21, 2025 |
| Study ends | April 30, 2030 |
| Registry record updated | April 21, 2026 |
| Trial ID | NCT04638088 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients scheduled for a planned radical prostatectomy.
✕Probably not a fit
Patients who refuse consent or lack French Health Care Insurance coverage may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of robot-assisted laparoscopy, conventional laparoscopy, and laparotomy in performing radical prostatectomy for prostate cancer. It aims to assess urinary and erectile function outcomes before and after surgery to determine the benefits of each surgical approach. The study addresses the lack of prior validation for robotic surgery in this context and seeks to provide reliable data to inform healthcare authorities and patients. By analyzing a large cohort of patients, the study hopes to clarify the real benefits of robotic surgery compared to traditional methods.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the most effective surgical approach for prostate cancer, potentially improving patient outcomes.
How similar studies have gone: Previous studies have indicated mixed results regarding robotic surgery's advantages, highlighting the need for this comprehensive evaluation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient hospitalized for a planned radical prostatectomy Exclusion Criteria: * Consent refusal from the patient * Patients protected by law (Art.L 1121-5, 1121-6, 1121-8 du Code de la santé publique) * Absence of a French Health Care Insurance coverage
Where it's running
-
Clinique Esquirol Saint Hilaire
Agen, France Recruiting -
Clinique Keraudren - CHPB
Brest, France Recruiting -
Centre Médico-Chirurgical Les Cèdres
Brive-la-Gaillarde, France Recruiting -
Polyclinique Montréal
Carcassonne, France Recruiting -
Pôle Santé République
Clermont-Ferrand, France Recruiting -
Clinique Emailleurs-Colombier
Limoges, France Recruiting
Show 24 more locations
-
Polyclinique de Poitiers
Poitiers, France Recruiting -
Clinique du Renaison
Roanne, France Recruiting -
Clinique Ambroise Paré
Toulouse, France Recruiting -
Clinique Rhône Durance
Avignon, France Completed -
Hôpital Privé La Châtaigneraie
Beaumont, France Completed -
Clinique St Vincent
Besançon, France Completed -
Polyclinique de Franche Comté
Besançon, France Completed -
Clinique de Saint Augustin
Bordeaux, France Completed -
Polyclinique Médipôle Saint-Roch
Cabestany, France Completed -
Polyclinique du Parc
Caen, France Completed -
Hôpital Privé Saint-François
Désertines, France Withdrawn -
Clinique Cap-d'Or
La Seyne-sur-Mer, France Completed -
Pôle Santé Sud
Le Mans, France Completed -
Polyclinique de Limoges
Limoges, France Completed -
Clinique Claude Bernard
Metz, France Withdrawn -
Polyclinique de Gentilly
Nancy, France Completed -
Clinique Saint-Augustin
Nantes, France Completed -
Polyclinique Grand Sud
Nîmes, France Completed -
Polyclinique Les Fleurs
Ollioules, France Completed -
Clinique Guillaume De Varye
Saint-Doulchard, France Completed -
Centre clinical
Soyaux, France Completed -
Clinique de l'Estrée
Stains, France Completed -
Polyclinique Vauban
Valenciennes, France Completed -
Hôpital privé Océane
Vannes, France Completed
Study contacts
- Principal investigator: Pierre-Thierry PIECHAUD, MD — Elsan
- Study coordinator: Shahnaz KLOUCHE, MD
- Email: klouche@elsan.care
- Phone: 00331 58 56 41 71
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.